Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sulfisoxazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 12/20 | 0.82 |
| ▸ | EDNRB | P24530 | 9/20 | 0.82 |
| ▸ | MEN1 | O00255 | 1/20 | 0.82 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.82 |
| ▸ | TSHR | P16473 | 1/20 | 0.82 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.82 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfisoxazole SCHEMBL23467 | 0.91 | EDNRA (1.00) | EDNRAEDNRBMEN1CYP2C9TSHR | |
| Sulfisoxazole SCHEMBL788644 | 0.91 | EDNRA (1.00) | EDNRAEDNRBMEN1CYP2C9TSHR | |
| Sulfisoxazole SCHEMBL23466 | 0.90 | EDNRA (0.79) | EDNRAEDNRBMEN1CYP2C9TSHR | |
| Sulfisoxazole SCHEMBL887764 | 0.90 | EDNRA (0.79) | EDNRAEDNRBMEN1CYP2C9TSHR | |
| Sulfisoxazole SCHEMBL5917298 | 0.90 | EDNRA (0.97) | EDNRAEDNRBMEN1CYP2C9TSHR | |
| Sulfisoxazole SCHEMBL2200933 | 0.90 | EDNRA (0.97) | EDNRAEDNRBMEN1CYP2C9TSHR | |
| Sulfisoxazole SCHEMBL5959142 | 0.87 | EDNRA (0.92) | EDNRAEDNRBMEN1CYP2C9TSHR | |
| Sulfisoxazole SCHEMBL16097888 | 0.86 | EDNRA (0.89) | EDNRAEDNRBMEN1CYP2C9TSHR | |
| Sulfisoxazole SCHEMBL20770061 | 0.84 | EDNRA (0.81) | EDNRAEDNRBMEN1CYP2C9TSHR | |
| Sulfisoxazole SCHEMBL28264710 | 0.84 | EDNRA (0.81) | EDNRAEDNRBMEN1CYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3106458-B1 | MALEIC ACID SALT OF ANTI-PRION COMPOUND, METHOD FOR PRODUCING THE SAME, AND PHARMACEUTICAL COMPOSITION OF THE SAME | UNIV GIFU (JP) | 2018-12-19 | — | — | EP | disclosed |
| US-9809563-B2 | Maleic acid salt of anti-prion compound, method for producing the same and pharmaceutical composition of the same | GIFU UNIVERSITY (JP) | 2017-11-07 | — | — | US | disclosed |
| US-9724312-B2 | Agent for the prevention, improvement or treatment of retinal disease | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2017-08-08 | — | — | US | disclosed |
| US-20160368885-A1 | MALEATE OF ANTI-PRION COMPOUND, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION THEREOF | NOBELPHARMA CO., LTD. (JP) | 2016-12-22 | — | — | US | disclosed |
| EP-3106458-A1 | MALEATE OF ANTI-PRION COMPOUND, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION THEREOF | Gifu University (JP) | 2016-12-21 | — | — | EP | disclosed |
| US-20160136275-A1 | OPHTHALMIC COMPOSITION | ROHTO PHARMA (JP) | 2016-05-19 | — | — | US | disclosed |
| US-20160089345-A1 | KIT OF OPHTHALMIC COMPOSITION | ROHTO PHARMA (JP) | 2016-03-31 | — | — | US | disclosed |
| US-20150025154-A1 | OPHTHALMIC COMPOSITION | ROHTO PHARMA (JP) | 2015-01-22 | — | — | US | disclosed |
| US-20140350119-A1 | OPHTHALMIC COMPOSITION COMPRISING GERANYLGERANYLACETONE | ROHTO PHARMA (JP) | 2014-11-27 | — | — | US | disclosed |
| US-20140243419-A1 | MUCOSALLY-APPLIED AGENT FOR PREVENTION, AMELIORATION OR TREATMENT OF RETINAL DISEASE | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2014-08-28 | — | — | US | disclosed |
| US-20140128475-A1 | AGENT FOR THE PREVENTION, IMPROVEMENT OR TREATMENT OF RETINAL DISEASE | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2014-05-08 | — | — | US | disclosed |
| US-8669241-B2 | Ophthalmic composition | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-11 | — | — | US | disclosed |
| US-20140045948-A1 | KIT OF OPHTHALMIC COMPOSITION | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2014-02-13 | — | — | US | disclosed |
| US-20130331458-A1 | KIT OF OPHTHALMIC COMPOSITION | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2013-12-12 | — | — | US | disclosed |
| US-20130303625-A1 | AGENT FOR THE PREVENTION, IMPROVEMENT OR TREATMENT OF RETINAL DISEASE | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2013-11-14 | — | — | US | disclosed |
| US-20130303627-A1 | OPHTHALMIC COMPOSITION | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2013-11-14 | — | — | US | disclosed |
| US-20130303626-A1 | OPHTHALMIC COMPOSITION | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2013-11-14 | — | — | US | disclosed |
| US-20130303624-A1 | OPHTHALMIC COMPOSITION COMPRISING GERANYLGERANYLACETONE | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2013-11-14 | — | — | US | disclosed |
| US-20100137252-A1 | Ophthalmic composition | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2010-06-03 | — | — | US | disclosed |
| US-20100069323-A1 | COMPOSITION FOR APPLICATION TO SKIN OR MUCOSA | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128475-A1 | AGENT FOR THE PREVENTION, IMPROVEMENT OR TREATMENT OF RETINAL DISEASE | ALDH1A2, ALDH1A3, PDE6D | EDNRA 1600/4885EDNRB 1654/4885MEN1 4614/4885 |
| US-20160368885-A1 | MALEATE OF ANTI-PRION COMPOUND, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION THEREOF | PRNP, MAPT, PSEN1 | EDNRA 4218/4885EDNRB 4508/4885MEN1 30/4885 |
| US-20140243419-A1 | MUCOSALLY-APPLIED AGENT FOR PREVENTION, AMELIORATION OR TREATMENT OF RETINAL DISEASE | ALDH1A2, AGER, GLA | EDNRA 1423/4885EDNRB 1661/4885MEN1 3297/4885 |
| US-20150025154-A1 | OPHTHALMIC COMPOSITION | GSTO1, GSTK1, GSTA1 | EDNRA 4582/4885EDNRB 4636/4885MEN1 4427/4885 |
| US-20130331458-A1 | KIT OF OPHTHALMIC COMPOSITION | KIT, F7, GGPS1 | EDNRA 4752/4885EDNRB 4582/4885MEN1 1703/4885 |
| US-20140045948-A1 | KIT OF OPHTHALMIC COMPOSITION | KIT, F7, GGPS1 | EDNRA 4752/4885EDNRB 4582/4885MEN1 1703/4885 |
| US-20160089345-A1 | KIT OF OPHTHALMIC COMPOSITION | KIT, F7, GGPS1 | EDNRA 4752/4885EDNRB 4582/4885MEN1 1703/4885 |
| US-20130303627-A1 | OPHTHALMIC COMPOSITION | GSTO1, GSTK1, GSTA1 | EDNRA 4582/4885EDNRB 4636/4885MEN1 4427/4885 |
| US-20130303625-A1 | AGENT FOR THE PREVENTION, IMPROVEMENT OR TREATMENT OF RETINAL DISEASE | ALDH1A2, ALDH1A3, PDE6D | EDNRA 1600/4885EDNRB 1654/4885MEN1 4614/4885 |
| US-20160136275-A1 | OPHTHALMIC COMPOSITION | PLPBP, CRYAA, CRYAB | EDNRA 4816/4885EDNRB 4749/4885MEN1 3077/4885 |
| US-20130303624-A1 | OPHTHALMIC COMPOSITION COMPRISING GERANYLGERANYLACETONE | ALDH1A2, PDE6C, PTGER3 | EDNRA 4400/4885EDNRB 4154/4885MEN1 4748/4885 |
| US-20130303626-A1 | OPHTHALMIC COMPOSITION | PLPBP, CRYAA, CRYAB | EDNRA 4816/4885EDNRB 4749/4885MEN1 3077/4885 |
| US-20140350119-A1 | OPHTHALMIC COMPOSITION COMPRISING GERANYLGERANYLACETONE | ALDH1A2, PDE6C, PTGER3 | EDNRA 4400/4885EDNRB 4154/4885MEN1 4748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.